# Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

> **NCT02031536** · PHASE2 · TERMINATED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 2 (actual)

## Conditions studied

- Gastrinoma
- Glucagonoma
- Insulinoma
- Liver Metastases
- Pancreatic Polypeptide Tumor
- Recurrent Islet Cell Carcinoma
- Somatostatinoma

## Interventions

- **DRUG:** everolimus
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT02031536
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-10
- **Primary completion:** 2017-07-19
- **Final completion:** 2017-07-19
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02031536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02031536, "Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02031536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*